All In Biotech

NDA 050779 · B Braun

Cefazolin and Dextrose

Cefazolin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Jul 27, 2000

Approved uses

5

Original approval plus efficacy supplements

Registered trials

207

37 Phase 3, 20 recruiting

FAERS reports

3,023

2,872 serious, 362 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 10, 2025.

Cefazolin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for: Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: ( 1 ) Respiratory tract infections ( 1.1 ) Urinary tract infections ( 1.2 ) Skin and skin structure infections ( 1.3 ) Biliary tract infections ( 1.4 ) Bone and joint infections ( 1.5 ) Genital infections ( 1.6 ) Septicemia ( 1.7 ) Endocarditis ( 1.8 ) Perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and Dextrose Injection and other antibacterial drugs, Cefazolin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ). 1.1 Respiratory Tract Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus and Streptococcus pyogenes in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration ( 2.1 , 2.2 , 2.4 , 2.5 ) and Use in Specific Populations (8.4) ] . Limitations of Use Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection and Dextrose Injection is indicated for the eradication of streptococci from the nasopharynx; however, data establishing...

Mechanism: Cefazolin is an antibacterial drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2024 Supplement 34 · Efficacy LetterLabel
  • Nov 23, 2020 Supplement 27 · Efficacy LabelLetter
  • Sep 18, 2014 Supplement 23 · Efficacy · priority review Letter
  • Jan 13, 2012 Supplement 18 · Efficacy LabelLetter
  • Jul 27, 2000 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
4 products under this application
  • CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
  • CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 3GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.

All 207 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic shock270
  • anaphylactic reaction164
  • hypotension154
  • pyrexia137
  • rash131
  • anaemia92
  • erythema92
  • nausea88
  • off label use84
  • pneumonia84
  • urticaria84
  • tachycardia83

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200429
200555
200644
200743
200853
200927
201050
2011106
2012192
201345
201456
201574
2016117
201783
2018121
2019148
2020148
2021139
2022296
2023318
2024357
2025319
2026203

Recalls

4 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Nov 21, 2013 · Class I · Terminated

    Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.

  • Nov 21, 2013 · Class I · Terminated

    Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 629 on PubMed

Sponsor: B Braun

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.